Initiation of protein synthesis: A target for antimicrobials

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 5, 2008, Pages 519-534

  Brandi, Letizia ^a   Fabbretti, Attilio ^b   Pon, Cynthia L ^b   Dahlberg, Albert E ^c   Gualerzi, Claudio O ^b,c  

^a Insubrias BioPark   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c BROWN UNIVERSITY   (United States)

Author keywords

Edeine; FMet tRNA; GE81112; Kasugamycin; MRNA; Orthosomycin; Oxazolidinones; Pactamycin; Thiostrepton; Trimethoprim

Indexed keywords

ACTINONIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVILAMYCIN; BB 86398; CHLORAMPHENICOL; DIHYDROFOLATE REDUCTASE INHIBITOR; DSM 14386; EDEINE; EVERNIMICIN; GE 81112; KASUGAMYCIN; LINCOMYCIN; LINEZOLID; MACROLIDE; METHOTREXATE; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; ORTHOSOMYCIN; OXAZOLIDINONE DERIVATIVE; PACTAMYCIN; PEPTIDE DEFORMYLASE INHIBITOR; PYRIMETHAMINE; SULFONAMIDE; THIOSTREPTON; TRIMETHOPRIM; VANCOMYCIN; VRC 3375; BACTERIAL PROTEIN; INITIATION FACTOR; PROTEIN SYNTHESIS INHIBITOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARCHAEBACTERIUM; BACTERIAL CELL; BINDING SITE; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EUKARYOTIC CELL; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PROTEIN SYNTHESIS; REVIEW; TRANSLATION INITIATION; URINARY TRACT INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; METABOLISM; PHYSIOLOGY; RNA TRANSLATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PHYSIOLOGY; BACTERIAL PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PEPTIDE INITIATION FACTORS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS;

EID: 43349101061     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.5.519     Document Type: Review

References (109)

1. Monaghan RL, Barrett JF. Antibacterial drug discovery-then, now and the genomics future. Biochem Pharmacol 2006;71:901-9
2. Tackling antibacterial resistance in Europe. European Academies Science Advisory Council Report, June 2007. Available from: http://www.easac.eu/ document.asp?id=68&pageno=1&detail=1&parent=31
3. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004;10:S122-9
4. Franceschi F, Duffy EM. Structure-based drug design meets the ribosome. Biochem Pharmacol 2006;7:1016-25
5. Brandi L, Fabbretti A, La Teana A, et al. Specific, efficient and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic. Proc Natl Acad Sci USA 2006;103:39-44
6. Bottger EC, Springer B, Prammananan T, et al. Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO Rep 2001;2:318-23
7. Londei P. Evolution of translational initiation: new insights from the archaea. FEMS Microbiol Rev 2005;29:185-200
8. Gualerzi CO, Pon CL. Initiation of mRNA translation in prokaryotes. Biochemistry 1990;29:5881-9
9. Gualerzi CO, Brandi L, Caserta E, et al. Role of the initiation factors in the early events of mRNA translation in bacteria. Cold Spring Harbor Symp Quant Biol 2001;66:363-76
10. Laursen BS, Sorensen HP, Mortensen KK, et al. Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev 2005;69:101-23
11. Pon CL, Gualerzi C. Effect of initiation factor 3 binding on the 30S ribosomal subunits of Escherichia coli. Proc Natl Acad Sci USA 1974;71:4950-4
12. Pon CL, Pawlik RT, Gualerzi C. The topographical localization of IF3 on E. coli 30S ribosomal subunits as a clue to its way of functioning. FEBS Lett 1982;137:163-7
13. Carter AP, Clemons WM Jr, Brodersen DE, et al. Crystal structure of an initiation factor bound to the 30S ribosomal subunit. Science 2001;291:498-501
14. Schuwirth BS, Borovinskaya MA, Hau CW, et al. Structures of the bacterial ribosome at 3.5Å resolution. Science 2005;310:827-34
15. Canonaco M, Gualerzi CO, Pon CL. Translation initiation factors affect an alternative occupancy of a dual ribosomal binding site by mRNA. Eur J Biochem 1989;182:501-6
16. La Teana A, Gualerzi CO, Brimacombe R. From stand-by to decoding site. Adjustment of the mRNA on the 30S ribosomal subunit under the influence of the initiation factors. RNA 1995;1:772-82
17. Yusupova G, Jenner L, Rees B, et al. Structural basis for messenger RNA movement on the ribosome. Nature 2006;444:391-4
18. Kaminishi T, Wilson DL, Takemoto C, et al. A snapshot of the 30S ribosomal subunit capturing mRNA via the Shine-Dalgamo interaction. Structure 2007;15:289-97
19. Tomsic J, Vitali LA, Daviter T, et al. Late events of translation initiation in bacteria: a kinetic analysis. EMBO J 2000;19:2127-36
20. Grigoriadou C, Marzi S, Kirillov S, et al. A qualitative kinetic scheme for 70S initiation complex formation. J Mol Biol 2007;373:562-72
21. Hennelly SP, Antoun A, Ehrenberg M, et al. A time-resolved investigation of ribosomal subunit association. J Mol Biol 2005;346:1243-58
22. Fabbretti A, Pon CL, Hennelly SP, et al. The real time path of IF3 onto and off the ribosome. Mol Cell 2007;25:285-96
23. Grigoriadou C, Marzi S, Pan D, et al. The translational fidelity function of IF3 during transition from the 30S initiation complex to the 70S initiation complex. J Mol Biol 2007;372:551-61
24. Gualerzi CO, Spurio R, La Teana A, et al. Site-directed mutagenesis of Escherichia coli translation initiation factors. Identification of the amino acids involved in ribosomal binding and recycling of IF1. Protein Eng 1989;3:133-8
25. Myasnikov AG, Marzi S, Simonetti A, et al. Conformational transition of initiation factor 2 from the GTP- to GDP-state visualized on the ribosome. Nat Struct Mol Biol 2005;12:1145-9
26. Allen GS, Zavialov A, Gursky R, et al. The cryo-EM structure of the translation initiation complex from Escherichia coli. Cell 2005;121:703-12
27. Spurio R, Brandi L, Caserta E, et al. The C-terminal subdomain (IF2 C-2) contains the entire fMet-tRNA binding site of initiation factor IF2. J Biol Chem 2000;275:2447-54
28. Guenneugues M, Meunier S, Boelens R, et al. Mapping the fMet-tRNA binding site of initiation factor IF2. EMBO J 2000;19:5233-49
29. Caserta E, Tomsic J, Spurio R, et al. Translation initiation factor IF2 interacts with the 30S subunit via two separate binding sites. J Mol Biol 2006;362:787-99
30. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5
31. Gale EF, Cundliffe E, Reynolds PE, et al. Antibiotic inhibitors of ribosome function. In: Molecular basis of antibiotic action. Wiley & Sons, London; 1981. p. 492-501
32. Dinos G, Wilson DN, Teraoka Y, et al. Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: the universally conserved residues G693 and C795 regulate P-site RNA binding. Mol Cell 2004;13:113-24
33. Adams JM, Capecchi MR. N-formylmethionyl-sRNA as the initiator of protein synthesis. Proc Natl Acad Sci USA 1966;55:147-55
34. Capecchi MR. Initiation of E. coli proteins. Proc Natl Acad Sci USA 1966;55:1517-24
35. Mayer C, Stortchevoi A, Köhrer C, et al. Initiator tRNA and its role in initiation of protein synthesis. Cold Spring Harb Symp Quant Biol 2001;66:195-206
36. Mechulam Y, Schmitt E, Maveyraud L, et al. Crystal structure of Escherichia coli methionyl-tRNA synthetase highlights species-specific features. J Mol Biol 1999;294:1287-97
37. Crepin T, Schmitt E, Blanquet S, et al. Structure and function of the C terminal domain of methionyl-tRNA synthetase. Biochemistry 2002;41:13003-11
38. fmet. EMBO J 1998;17:6819-26
39. Eisenstadt J, Lengyel P. Formylmethionyl-tRNA dependence of amino acid incorporation in extracts of trimethoprim-treated Escherichia coli. Science 1966;154:524-7
40. Wooden JM, Hartwell LH, Vasquez B, et al. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol 1997;85:25-40
41. Mazel D, Pochet S, Marliere P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 1994;13:914-23
42. Giglione C, Pierre M, Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 2000;36:1197-205
43. Yuan Z, Trias J, White RJ. Deformylase as a novel antibacterial target. Drug Discov Today 2001;6:954-61
44. Clements JM, Beckett RP, Brown A, et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 2001;45:563-70
45. Chen D, Hackbarth C, Ni ZJ, et al. Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother 2004;48:250-61
46. Vaughan MD, Sampson PB, Honek JF. Methionine in and out of proteins: targets for drug design. Curr Med Chem 2002;9:385-409
47. Greis KD, Zhou S, Siehnel R, et al. Development and validation of a whole-cell inhibition assay for bacterial methionine aminopeptidase by surace-enhanced laser desorption ionization-time of flight mass spectrometry. Antimicrob Agents Chemother 2005;49:3428-34
48. Vazquez D. Inhibitors of protein synthesis. Mol Biol Biochem Biophys 1979;30:1-312
49. Pestka S. Inhibitors of protein synthesis. In: Weissbach H, Pestka S, editors, Molecular mechanism of protein biosynthesis. Academic Press: New York, San Francisco, London; 1977. p. 467-553
50. Altamura S, Sanz JL, Amils R, et al. The antibiotic sensitivity spectra of ribosomes from the Thermoproteales: phylogenetic depth and distribution of antibiotic binding sites. Syst Appl Microbiol 1988;10:218-25
51. Szer W, Kurylo-Borowska Z. Effect of edeine on aminoacyl-tRNA binding to ribosomes and its relationship to ribosomal binding sites. Biochim Biophys Acta 1970;224:477-86
52. Brodersen DE, Clemons WM Jr, Carter AP, et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000;103:1143-54
53. Pioletti M, Schluenzen F, Harms J, et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J 2001;20:1829-39
54. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987;327:389-94
55. Berk V, Zhang W, Pai RD, Cate JHD. Structural basis for mRNA and tRNA positioning on the ribosome. Proc Natl Acad Sci USA 2006;103:15830-4
56. Korostolev A, Trakhanov S, Laurberg M, Noller HF. Crystal structure of a 70S ribosome-tRNA complex reveals functional interactions and rearrangements. Cell 2006;126:1065-77
57. Kozak M, Shatkin AJ. Migration of 40S ribosomal subunits on messenger RNA in the presence of edeine. J Biol Chem 1978;253:6568-77
58. Woodcock J, Moazed D, Cannon M, et al. Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA. EMBO J 1991;10:3099-103
59. Mankin AS. Pactamycin resistance mutations in functional sites of 16S rRNA. J Mol Biol 1997;274:8-15
60. Moazed D, Noller HF. Binding of tRNA to the ribosomal A and P sites protects two distinct sets of nucleotides in 16S rRNA. J Mol Biol 1990;211:135-45
61. Cohen LB, Goldberg IH, Herner AE. Inhibition by pactamycin of the initiation of protein synthesis. Effect on the 30S ribosomal subunit. Biochemistry 1969;8:1327-35
62. Schluenzen F, Takemoto C, Wilson DN, et al. The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat Struct Mol Biol 2006;13:871-8
63. Okuyama A, Tanaka N, Komai T. The binding of kasugamycin to the Escherichia coli ribosomes. J Antibiot 1975;28:903-5
64. Okuyama A, Machiyama N, Kinoshita T, Tanaka N. Inhibition by kasugamycin of initiation complex formation on 30S ribosomes. Biochem Biophys Res Commun 1971;43:196-9
65. Poldermans B, Goosen N, Van Knippenberg PH. Studies on the function of two adjacent N6,N6-dimethyladenosines near the 3′ end of 16S ribosomal RNA of Escherichia coli. I. The effect of kasugamycin on initiation of protein synthesis. J Biol Chem 1979;254:9085-9
66. Schuwirth BS, Day JM, Hau CW, et al. Structural analysis of kasugamycin inhibition of translation. Nat Struct Mol Biol 2006;13:879-86
67. Vila-Sanjurjo A, Squires CL, Dahlberg AE. Isolation of Kasugamycin resistant mutants in the 16S rRNA of E. coli. J Mol Biol 1999;293:1-8
68. Moll I, Bläsi U. Differential inhibition of 30S and 70S translation initiation complexes on leaderless mRNA by kasugamycin. Biochem Biophys Res Commun 2002;297:1021-6
69. Brandi L, Lazzarini A, Cavaletti L, et al. Novel tetrapepride inhibitors of bacterial protein synthesis produced by a Streptomyces sp. Biochemistry 2006;45:3692-702
70. Brandi L, Fabbretti A, Milon P, et al. Methods for identifying compounds that specifically target translation. Methods Enzymol 2007;431:229-67
71. Hausner TP, Geigenmüller U, Nierhaus KH. The allosteric three-site model for the ribosomal elongation cycle. New insights into the inhibition mechanisms of aminoglycosides, thiostrepton and viomycin. J Biol Chem 1988;263:13103-11
72. Moazed D, Robertson JM, Noller HF. Interaction of elongation factors EF-G and EF-Tu with a conserved loop in 23S RNA. Nature 1988;334:362-64
73. Cundliffe E. Recognition sites for antibiotics within rRNA. In: Hill WE, Dahlberg A, Garrett RA, et al., editors, The ribosome. ASM Press: Washington DC; 1990. p. 479-90
74. Porse BT, Leviev I, Mankin AS, Garrett RA. The antibiotic thiostrepton inhibits a functional transition within protein L11 at the ribosomal GTPase centre. J Mol Biol 1998;276:391-404
75. Rodnina MV, Savelsbergh A, Matassova NB, et al. Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. Proc Natl Acad Sci USA 1999;96:9586-90
76. Cameron DM, Thompson J, March PE, et al. Initiation factor IF2, thiostrepton and micrococcin prevent the binding of elongation factor G to the Escherichia coli ribosome. J Mol Biol 2002;319:27-35
77. Brandi L, Marzi S, Fabbretti A, et al. The translation initiation functions of IF2: targets for thiostrepton inhibition. J Mol Biol 2004;335:881-94
78. Treede I, Jakobsen L, Kirpekar F, et al. The avilamycin resistance determinants AviRa and AviRb methylate 23S rRNA at the guanosine 2535 base and the uridine 2479 ribose. Mol Microbiol 2003;49:309-18
79. McNicholas PM, Najarian DJ, Mann PA, et al. Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both Gram positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000;44:1121-6
80. Belova L, Tenson T, Xiong L, et al. A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit. Proc Natl Acad Sci USA 2001;98:3726-31
81. Mankin AS. Ribosomal antibiotics. Mol Biol 2001;35:509-20
82. Adrian PV, Mendrick C, Loebenberg D. Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants. Antimicrob Agents Chemother 2000;44:3101-06
83. Kofoed CB, Vester B. Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA. Antimicrob Agents Chemother 2002;46:3339-42
84. Aarestrup FM, Jensen LB. Presence of variations in ribosomal protein L16 corresponding to susceptibility of enterococci to oligosaccharides (avilamycin and evernimicin). Antimicrob Agents Chemother 2000;44:3425-27
85. Adrian PV, Zhao W, Black TA, et al. Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action. Antimicrob Agents Chemother 2000;44:732-8
86. McNicholas PM, Mann PA, Najarian DJ, et al. Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin. Antimicrob Agents Chemother 2001;45:79-83
87. Ban N, Nissen P, Hansen J, et al. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 2000; 289:905-20
88. Harms J, Schluenzen F, Zarivach R, et al. High resolution structure of the large ribosomal subunit from a mesophilic eubacterium. Cell 2001;107:679-88
89. Mann PA, Xiong L, Mankin AS, et al. EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance. Mol Microbiol 2001;41:1349-56
90. La Teana A, Gualerzi CO, Dahlberg AE. Initiation factor IF 2 binds to the alpha-sarcin loop and helix 89 of Escherichia coli 23S ribosomal RNA. RNA 2001;7:1173-9
91. Marzi S, Knight W, Brandi L, et al. Ribosomal localization of translation initiation factor IF2. RNA 2003;9:958-69
92. Zurenko GE, Gibson JK, Shinabarger DL, et al. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol 2001;1:470-6
93. Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007;26:393-402
94. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41:2127-31
95. Matassova NB, Rodnina MV, Endermann R, et al. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 1999;5:939-46
96. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5
97. Colca JR, McDonald WG, Waldon DJ, et al. Cross-linking in the living cell locates the site of action of Oxazolidinone antibiotics. J Biol Chem 2003;278:21972-9
98. Thompson J, O'Connor M, Mills JA, Dahlberg AE. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol 2002;322:273-9
99. Aoki H, Ke L, Poppe SM, et al. Oxazolidinone antibiotics target the P-site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002;46:1080-5
100. Patel U, Yan YP, Hobbs FW Jr, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J Biol Chem 2001;276:37199-205
101. Wilson DN, Harms JM, Nierhaus KH, et al. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol Chem 2005;386:1239-52
102. Milon P, Konevega AL, Peske F, et al. Transient kinetics, fluorescence, and FRET in studies of initiation of translation in bacteria. Methods Enzymol 2007;430:1-30
103. Ondeyka JG, Zink D, Basilio A, et al. Coniothyrione, a chlorocyclopentandienyl-benzopyrone as a bacterial protein synthesis inhibitor discovered by antisense technology. J Nat Prod 2007;70:668-70
104. Dermyer M, Wise SC, Braden T, Holler TP. Simultaneous screening of multiple bacterial tRNA synthetases using an Escherichia coli S30-based transcription and translation assay. Assay Drug Dev Technol 2007;5:515-21
105. Brandi L, Dresios J, Gualerzi CO. Assays for the identification of inhibitors targeting specific translational steps. Methods Mol Med 2008;142:87-105
106. Riedlinger J, Reicke A, Zähner H, et al. Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucosispora strain AB-18-032. J Antibiot 2004;57:271-9
107. Li X, Qin L. Metagenomics-based drug discovery and marine microbial diversity. Trends Biotech 2005;23:539-43
108. Tenson T, Mankin A. Antibiotics and the ribosome. Mol Microbiol 2006;59:1664-77
109. Korostelev A, Trakhanov S, Asahara H, et al. Interactions and dynamics of the Shine Dalgarno helix in the 70S ribosome. Proc Natl Acad Sci USA 2007;104:16840-3